Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Micheli

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
HIV Medicine|August 2, 2016
Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacyL Milazzo, A Lai, E Calvi, et al.
Emerging Microbes & Infections|February 24, 2022
Reduced neutralization of SARS-CoV-2 Omicron variant by BNT162b2 vaccinees' sera: a preliminary evaluationD Mileto, V Micheli, C Fenizia, et al.
Journal of Neurology|April 26, 2012
Clinical and biochemical improvement following HSCT in a patient with MNGIE: 1-year follow-upF Sicurelli, M A Carluccio, F Toraldo, et al.
Emerging Microbes & Infections|February 25, 2022
Viro-immunological evaluation in an immunocompromised patient with long-lasting SARS-CoV-2 infectionA Mancon, A Rizzo, D Mileto, et al.
Antiviral Research|September 17, 2011
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugsR Salpini, V Svicher, V Cento, et al.
Chemico-Biological Interactions|April 18, 2001
Modulation of aldose reductase activity through S-thiolation by physiological thiolsM Cappiello, P Amodeo, B L Mendez, et al.
The Journal of Antimicrobial Chemotherapy|July 18, 2009
Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictorsL Bracciale, M Colafigli, M Zazzi, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|January 8, 2013
Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA databaseS Rusconi, P Vitiello, F Adorni, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 30, 2018
Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA)S Rusconi, F Adorni, P Tau, et al.
Journal of Medical Virology|April 17, 2013
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practiceR Salpini, C Alteri, V Cento, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
HIV Medicine|August 2, 2016
Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacyL Milazzo, A Lai, E Calvi, et al.
Emerging Microbes & Infections|February 24, 2022
Reduced neutralization of SARS-CoV-2 Omicron variant by BNT162b2 vaccinees' sera: a preliminary evaluationD Mileto, V Micheli, C Fenizia, et al.
Journal of Neurology|April 26, 2012
Clinical and biochemical improvement following HSCT in a patient with MNGIE: 1-year follow-upF Sicurelli, M A Carluccio, F Toraldo, et al.
Emerging Microbes & Infections|February 25, 2022
Viro-immunological evaluation in an immunocompromised patient with long-lasting SARS-CoV-2 infectionA Mancon, A Rizzo, D Mileto, et al.
Antiviral Research|September 17, 2011
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugsR Salpini, V Svicher, V Cento, et al.
Chemico-Biological Interactions|April 18, 2001
Modulation of aldose reductase activity through S-thiolation by physiological thiolsM Cappiello, P Amodeo, B L Mendez, et al.
The Journal of Antimicrobial Chemotherapy|July 18, 2009
Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictorsL Bracciale, M Colafigli, M Zazzi, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|January 8, 2013
Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA databaseS Rusconi, P Vitiello, F Adorni, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 30, 2018
Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA)S Rusconi, F Adorni, P Tau, et al.
Journal of Medical Virology|April 17, 2013
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practiceR Salpini, C Alteri, V Cento, et al.
Pageof 11